Solid Biosciences Receives FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia

- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -

- SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA -

- Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 -

- Expands Solid's clinical pipeline to include first cardiac indication with urgent unmet medical need -